Investigating a new treatment for Alzheimer's disease
Official title: A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study
Funded at Oligomerix, INC · NIH-10710197 · Data updated 2026-11-12
This study is looking into a new oral medication for Alzheimer's disease to see how well it works by checking certain markers in the blood and spinal fluid of participants, and it's aimed at helping those affected by this condition find better treatment options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oligomerix, INC NIH-funded |
| Lab location | 1 site (White Plains, UNITED STATES) |
| Project start | September 30, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,367,955 |
| NIH project number | 5R44AG077991-02 |
| Project ID | NIH-10710197 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who are seeking new treatment options.
✕Less likely to help
Patients with other forms of dementia or those not diagnosed with Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on preparing for a Phase 1b clinical study that aims to evaluate the effectiveness of a new oral medication for Alzheimer's disease. The study will assess early clinical signs of efficacy by measuring specific biomarkers in the blood and cerebrospinal fluid of participants. It is designed to support longer-term dosing to observe any changes in these biomarkers, which could indicate the drug's potential to modify the disease. The research is particularly relevant given the increasing prevalence of Alzheimer's disease and the urgent need for effective treatments.
Why it matters
Potential benefit: If successful, this research could lead to a new, cost-effective treatment that modifies the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in similar approaches targeting biomarkers in Alzheimer's disease, indicating potential for success.
Where this research is happening
-
Oligomerix, INC
White Plains, United States Active
Researchers
- Principal investigator: Moe, James G. — Oligomerix, INC
- Study coordinator: Moe, James G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.